ClinicalTrials.gg
Not yet recruitingNCT03505346Updated Nov 21, 2023

68 Ga-NODAGA-E[c(RGDγK)]2: Positron Emission Tomography Tracer for Imaging of Angiogenesis in Ischemic Heart Disease

A Phase 2 interventional study of 68Ga-NODAGA-E[c(RGDyK)]2 in Chronic Ischemic Heart Disease, sponsored by Rigshospitalet, Denmark. Not yet recruiting at 1 site in Denmark. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-11-21.

Sponsored by Rigshospitalet, Denmark · Phase 2, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Non-randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Myocardial Ischemia by Rigshospitalet, Denmark — 3 open to participants now, 3 under way, none of them phase 3. Myocardial Ischemia · Rigshospitalet, Denmark.

Planned enrollment
8th of 12
42 · median 54
Started
2024
the only one that year
Phase 2
2 of 13
1 open now
Registered
9th of 13
by date

Among the 13 studies in Myocardial Ischemia by Rigshospitalet, Denmark, this one is the 8th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2024, is one of 2 in phase 2, and was the 9th registered.

Myocardial Ischemia

1,123 studies on the registry are indexed under Myocardial Ischemia; 177 are open to participants now.

Browse Myocardial Ischemia studies →

Open to participants now

3 of the 13 studies in Myocardial Ischemia by Rigshospitalet, Denmark are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 135 Myocardial Ischemia studies recruiting now, 92 (68%) set no upper age limit and 6 (4%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Myocardial Ischemia by Rigshospitalet, Denmark, or all of them as a file.
02

Study summary

The aim is to examine the expression of αvβ3 integrin using a novel selective radiotracer in patients with chronich ischemic heart disease and investigate if it is a suitable tool for predicting myocardial recovery and thus prognosis after intervention.

Read the detailed description

Ischemic heart disease is worldwide the single most frequent cause of death. The number of patients surviving acute myocardial injury is increasing due to improved acute treatment. However, after the initial repair, the tissue undergoes a remodeling phase to compensate for the damaged area. This re-modeling phase can change the structure end geometry of the heart resulting in lower ejection fraction, leading to cardiac dysfunction, which eventually leads to heart failure. Ischemic heart disease is most commently caused by arteriosclerosis of the coronary artery.

If chronic ischemic heart disease is left untreated, it will lead to symptoms to the patient. These symptons occur when the myocardiel oxygen demand exceeds the oxygen provided, due to coronary occlusion.

If the heart suffers from ischemia, the tissue reacts strongly to the hypoxia. The body will as a compensatory mechanism create new vessel to provide the tissue with oxygen. This is known as the biological process of angiogenesis. This complex process involves different angiogenic and pro-fibrotic transcription factors that initiate the restoration of capillaries by sprouting from the existing endothelial cells in response to hypoxia.

Integrin αvβ3 is a transmembrane cell surface receptor that is markedly upregulated in states of angiogenesis. It facilitates migration and proliferation and thereby allowing cells to respond to extracellular environment. Integrin αvβ3 is thus a key player in the angiogenic process. The integrin αvβ3 has a binding site for an RGD peptide (Arg-Gly-Asp motif) and this can be targeted by PET tracers.

RGD-based PET tracers have been shown to accumulate at the site of myocardial necrosis in both human and animal studies. The uptake before interventions may correlate to recovery of cardiac function and thus serve as a prognostic marker after intervention.

03

Conditions studied

  • Chronic Ischemic Heart Disease

Browse trials for

Keywords

  • Positron Emission Tomography
  • nuclear medicine
  • prognosis
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age over 50 years
  • Patient with known chornic ischemic Heart disease admitted to Rigshospitalet to either PCI og CABG

Exclusion criteria

Exclusion Criteria:

  • No prior history of Heart surgery
  • Not treated with anti-angiogenic medicine
  • Subject with pacemaker, cochlear implant or insulin pump
  • Pregnancy
  • Lactation
  • Severe claustrophobia
  • Severe obesity (weight above 140kg)
  • Conversion from PCI to CABG
  • If a subject is in the fertile age, a pregnancy test will be use prior to injection to the PET_tracer
  • If a subject is having a severe allergic reaction to the PET-tracer, the person will be excluded for the rest of the trial
  • If the PET-tracer is administered subcutaneous, the person will be excluded for the rest of the trial¨
  • Type I or II diabetes
05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    percutanous coronary intervention(PCI)

    200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 administered IV. two times. 14-21 days before intervention and 30-35 days after intervention

    Drug: 68Ga-NODAGA-E[c(RGDyK)]2

  • Experimental
    Coronary artery bypass-graft(CABG)

    200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 administered IV. two times. 14-21 days before intervention and 30-35 days after interventionintervention

    Drug: 68Ga-NODAGA-E[c(RGDyK)]2

Interventions

  • Drug68Ga-NODAGA-E[c(RGDyK)]2

    200 MBq 68Ga-NODAGA-E\[c(RGDyK)\]2 administered IV.

    Also known as: RGD-PET

06

What researchers measure

Primary outcomes

  1. To evaluate myocardial angiogenesis

    Analysing change in uptake of 68Ga-NODAGA-E\[c(RGDyK)\]2 Positron Emission Tomography after intervention

    Time frame: 30-35 days

Secondary outcomes

  1. Correlation between 68Ga-NODAGA-E[c(RGDyK)]2 and myocardial perfusion

    Correlation between uptake of 68Ga-NODAGA-E\[c(RGDyK)\]2 and change in myocardial perfusion after intervention using Rubidium 82 Positron Emission Tomography

    Time frame: 30-35 days

  2. Correlation between 68Ga-NODAGA-E[c(RGDyK)]2 and functional recovery

    Correlation between uptake of 68Ga-NODAGA-E\[c(RGDyK)\]2 and functional recovery using Magnetic Resonance after intervention

    Time frame: 30-35 days

  3. Correlatino between 68Ga-NODAGA-E[c(RGDyK)]2 and viability

    Correlation between uptake of 68Ga-NODAGA-E\[c(RGDyK)\]2 and viability using Flour-Deoxy-Glucose Positron Emission Tomography after intervention

    Time frame: 30-35 days

07

Study locations

1 site
  • Department of Physiology, Nuclear Medicine and PET
    Copenhagen, Region Hovedstaden 2100, Denmark
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2024; primary completion for Dec 2025, 23 months later.

Of 16 phase 2 interventional studies under Myocardial Ischemia, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 47. This study's planned 23 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2018
First posted
Apr 23, 2018
StartEst.
Jan 1, 2024
Primary completionEst.
Dec 1, 2025
CompletionEst.
Dec 1, 2025
Last update
Nov 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03505346
Responsible party
Simon Bentsen (Medical doctor, Rigshospitalet, Denmark) — Principal investigator
First posted
Apr 23, 2018
Start date
Jan 1, 2024 (estimated)
Primary completion
Dec 1, 2025 (estimated)
Completion
Dec 1, 2025 (estimated)
Last update
Nov 21, 2023

Study contacts

Simon Bentsen, MD
Contact
simon.bentsen.01@regionh.dk
+4535451793
Rasmus Ripa, MD
Contact
rasmus.ripa@regionh.dk
+4535454011
Andreas Kjær, MD
study director · Rigshospitalet, Denmark

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion